OncoMatch/Clinical Trials/NCT06472739

The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving Radiotherapy

Is NCT06472739 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies GM-CSF for gm-csf.

Phase 2RecruitingSun Yat-sen UniversityNCT06472739Data as of May 2026

Treatment: GM-CSF — To evaluate the efficacy of GM-CSF to preventing oral mucositis for patients with nasopharyngeal carcinoma receiving radiotherapy.

Check if I qualify

Extracted eligibility criteria

Disease stage

Required: Stage II, III, IVA

Excluded: Stage I, IVB

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: radiotherapy

Exception: except for non-melanomatous skin cancers outside intended RT treatment volume

History of previous radiotherapy (except for non-melanomatous skin cancers outside intended RT treatment volume)

Cannot have received: chemotherapy

Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes

Cannot have received: surgery

Exception: except diagnostic

Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes

Lab requirements

Blood counts

wbc≥4×109/l, plt≥100×109/l, hgb≥90g/l

Kidney function

creatinine clearance rate≥60 ml/min or creatinine< 1.5×uln

Liver function

alt, ast <1.5×uln concomitant with alp ≤2.5×uln, and bilirubin ≤uln

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify